HealthcareMRR2

  Narcolepsy Market Increasing  prevalence of narcolepsy , growing the obese population, increasing demands for effective treatment, rising research and development are estimated to be some of the significant drivers for the global narcolepsy market. However, lack of awareness and low per capita healthcare expenditure in the middle and low-income countries may restraint the global narcolepsy market growth, during the forecast period. Narcolepsy Market  is expected to register a CAGR of 9.7 % with USD 6.9 Billion by 2030 Major Key Players: Some of the major market players in the global narcolepsy market are Jazz Pharmaceuticals plc (Republic of Ireland), BIOPROJET (Paris), Arena Pharmaceuticals, Inc. (U.S.), Graymark Healthcare, Inc. (U.S.), Mylan N.V.  (U.S., Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Shire (Republic of Ireland), Shionogi Inc. (U.S.), Ligand Pharmaceuticals, Inc. (U.S.), and others. Segment Analysis The Global Narcolepsy...

  Narcolepsy Market Increasing  prevalence of narcolepsy , growing the obese population, increasing demands for effective treatment, rising research and development are estimated to be some of the significant drivers for the global narcolepsy market. However, lack of awareness and low per capita healthcare expenditure in the middle and low-income countries may restraint the global narcolepsy market growth, during the forecast period. Major Key Players: Some of the major market players in the global narcolepsy market are Jazz Pharmaceuticals plc (Republic of Ireland), BIOPROJET (Paris), Arena Pharmaceuticals, Inc. (U.S.), Graymark Healthcare, Inc. (U.S.), Mylan N.V.  (U.S., Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), Shire (Republic of Ireland), Shionogi Inc. (U.S.), Ligand Pharmaceuticals, Inc. (U.S.), and others. Increasing prevalence of narcolepsy and growing obese population will encourage the global  narcolepsy market  to grow at...